Psychiatry and Adolescent Mental Health
Gedeon Richter Plc. supports clinical research in schizophrenia affecting adolescents aged 13 to 17 years, with a focus on treatment needs specific to this age group.
- Adolescent schizophrenia
- Psychiatric care
- Early-onset mental illness
The sponsor’s research activity is centered on understanding therapeutic options for young patients living with serious psychiatric disorders.
Antipsychotic Therapy
Its clinical programme includes work on cariprazine, an antipsychotic used in the management of schizophrenia, with attention to both symptom control and treatment safety.
- Cariprazine
- Antipsychotic treatment
- Schizophrenia management
This area reflects interest in pharmacologic approaches for psychiatric disorders in younger populations.
Long-term Safety and Tolerability
The sponsor funds research examining the safety and tolerability of psychiatric treatment in adolescents, with emphasis on sustained use in a vulnerable population.
- Long-term safety
- Tolerability
- Adolescent treatment safety
These studies address the clinical need for age-appropriate monitoring of antipsychotic therapy.
Efficacy Evaluation in Psychiatric Disorders
Clinical research also covers the efficacy of treatment options for adolescent schizophrenia, supporting assessment of therapeutic benefit in relation to placebo.
- Treatment efficacy
- Placebo comparison
- Therapeutic response
This work is directed toward defining effective medication options for adolescents with serious mental illness.
